<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600167</url>
  </required_header>
  <id_info>
    <org_study_id>NIMR-MB-002</org_study_id>
    <nct_id>NCT04600167</nct_id>
  </id_info>
  <brief_title>Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus</brief_title>
  <acronym>PROTID</acronym>
  <official_title>A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Nyanda Elias Ntinginya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otago University, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St George's, University of London, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kilimanjaro Christian Medical University College (KCMUCo), Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uganda Martyrs Hospital Lubaga, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute for Medical Research, Tanzania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient&#xD;
      outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB&#xD;
      and HIV and it has been estimated that 15-30% of TB disease may be attributable to diabetes&#xD;
      globally. This may be expected to rise substantially as DM prevalence increases. Treatment of&#xD;
      Latent TB Infection (LTBI) in this population will likely have a significant clinical&#xD;
      benefit. Similar to HIV-infected individuals, those with DM might benefit from therapy to&#xD;
      prevent the development of TB disease. Current international guidelines do not recommend LTBI&#xD;
      management in people with DM, but this is because no studies have examined the risk-benefit&#xD;
      ratio of such an intervention. To date, no RCTs have been conducted to investigate the&#xD;
      efficacy and safety of preventive treatment of LTBI in DM patients. Based on evidence on&#xD;
      effectiveness, safety, and treatment completion rates, 3HP has been selected as the regimen&#xD;
      of choice for this study of African people living with DM. People living with DM will be&#xD;
      randomized to 3HP or placebo to determine the efficacy of 3HP in the prevention of TB disease&#xD;
      in this population. PROTID's preventive treatment of LTBI among people with DM will generate&#xD;
      the first solid evidence to support or refute the use of preventive treatment against TB in&#xD;
      people with DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First diagnosis of TB</measure>
    <time_frame>Through study completion, median of 33 months follow-up</time_frame>
    <description>The primary outcome will compare the rate of occurrence of TB disease (defined as definite or probable TB) in treatment and control groups. Definite TB disease will be confirmed by a culture or Xpert positive result for M. tuberculosis. Probable TB will be diagnosed according to an algorithm that takes into account symptoms, chest x-ray reading, sputum smear, histology and verbal autopsy results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of possible, probable or definite TB disease</measure>
    <time_frame>At least 24 months post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of an adverse event</measure>
    <time_frame>From randomisation to 60 days after end of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment completion</measure>
    <time_frame>Defined as &gt; 11 of 12 doses of treatment over no more than 16 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>At least 24 months post randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of possible, probable, or definite TB, or death</measure>
    <time_frame>At least 24 months post randomisation</time_frame>
    <description>Occurrence of possible, probable, or definite TB, or death, noting that a proportion of deaths are likely to be due to TB but not possible to confirm through verbal autopsy and clinical notes review.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Isoniazid and Rifapentine (INH-RPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the control arm will receive placebo once weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid and Rifapentine (INH-RPT)</intervention_name>
    <description>Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.</description>
    <arm_group_label>Isoniazid and Rifapentine (INH-RPT)</arm_group_label>
    <other_name>3HP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in the control group will receive placebo once weekly for 12 weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Enrolled in diabetes care with a history of DM and current use of anti-diabetic&#xD;
             medication ('known DM'); OR in the absence of anti-diabetic medication an HbA1c of&#xD;
             =6.5% (48 mmol/mol) or a fasting venous plasma glucose of =7.0 mmol (126 mg/dl). For&#xD;
             those with no previously known DM a repeat test above the diagnostic cut-point is&#xD;
             required to confirm the diagnosis ('new DM')&#xD;
&#xD;
          2. Adult (18 years or older)&#xD;
&#xD;
          3. Diagnosed with LTBI, defined as a positive IGRA test or TST reactivity =10 mm&#xD;
&#xD;
          4. Voluntarily signed Informed Consent Form&#xD;
&#xD;
          5. If sexually active, willing to use an effective contraceptive method for the duration&#xD;
             of preventive therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Weight &lt;45 kg&#xD;
&#xD;
          2. Previous TB disease, defined as either bacteriologically confirmed or clinically&#xD;
             diagnosed and treated&#xD;
&#xD;
          3. Treatment with a rifamycin medication or isoniazid in the previous 2 years.&#xD;
&#xD;
          4. Diagnosis of probable or definite TB during screening&#xD;
&#xD;
          5. Confirmed HIV-infection or receiving antiretroviral treatment&#xD;
&#xD;
          6. Liver dysfunction, defined as serum aspartate aminotransferase (AST) level 5 times the&#xD;
             upper limit of normal&#xD;
&#xD;
          7. Pregnant or planning to become pregnant in the next 3 months, or lactating&#xD;
&#xD;
          8. Known allergy/sensitivity or any hypersensitivity to components of study drugs or&#xD;
             their formulation&#xD;
&#xD;
          9. Other conditions inapplicable for participation in this study, such as likely to fail&#xD;
             to adhere to study commitment or to complete the whole study, at the discretion of the&#xD;
             site investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nyanda E Ntinginya, MD, MSc., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Mbeya Medical Research Center, National Institute for Medical Research, Tanzania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nyasatu Chamba, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kilimanjaro Christian Medical Centre,Moshi,Tanzania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Andia- Biraro, MD., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University, Makerere, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davis Kibirige, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martyrs Hospital Lubaga, Makerere, Uganda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Issa Sabi, MD.</last_name>
    <phone>+255 25 250 3364</phone>
    <email>isabi@nimr-mmrc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nyanda E Ntinginya, MD., MSc., PhD.</last_name>
    <phone>+255 25 250 3364</phone>
    <email>nelias@nimr-mmrc.org</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Medical Research, Tanzania</investigator_affiliation>
    <investigator_full_name>Dr. Nyanda Elias Ntinginya</investigator_full_name>
    <investigator_title>Director, NIMR - Mbeya Medical Research Centre</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Drugs</keyword>
  <keyword>Social science</keyword>
  <keyword>Health systems</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

